Developing a nanomachine which associates with nucleic acid pharmaceuticals in a rendezvous like manner in vivo to target brain tumors

A research group of Kazunori KATAOKA (Director General, iCONM / Professor, The University of Tokyo Institute for Future Initiatives) and Kanjiro MIYATA (Associate Professor, Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo) and, Yutaka KONDO (Professor, Nagoya University Graduate School of Medicine) , succeeded in developing the Nucleic Acid Medicine-loaded Nanomachine, a technology that can stably protect nucleic acid drugs that are prone to deactivation in the bloodstream and deliver them to intractable cancers such as pancreatic cancer and brain tumors.

Currently, efforts are underway to make this nucleic acid-based nanomachine practical as a drug. There is great promise for emerging new treatments for pancreatic cancer and brain tumors.

The results of this research were published in "Nature Communications" on Apr. 24.

Click here for details.

• 
  【Dr. Kazunori Kataoka】
• 
  【Dr. Kanjiro Miyata】

• 
  【Ms. Kazuko Tou】
• 
  【Mr. Kotaro Hayashi】